Overview

Treatment of Plantar Fasciitis With Xeomin

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The plantar fascia is an inelastic, broad band of tissue on the plantar or undersurface of the foot. Plantar fasciitis is an inflammation of the plantar fascia that causes heel and foot pain. The current standard orthopaedic management of plantar fasciitis begins with nonsurgical treatment modalities. Surgical treatment of plantar fasciitis is indicated only if nonsurgical means fail. A newer method of treating plantar fasciitis before resorting to surgery is the use of Botulinum Toxin or Xeomin (incobotulinum toxin A, Merz USA). Treatment of plantar fasciitis with Xeomin is important, as there are limited studies on the subject to date. The purpose of this study is to examine the long-term results of using Xeomin to treat plantar fasciitis in one physician's (J.A.) practice at Rothman Institute Orthopaedics through a placebo-controlled, randomized, double-blinded study.
Phase:
Phase 4
Details
Lead Sponsor:
Rothman Institute Orthopaedics
Collaborators:
Merz North America, Inc.
Merz Pharmaceuticals, LLC
Treatments:
incobotulinumtoxinA